Kenneth Rosenzweig, MD
Dr. Kenneth Rosenzweig is a radiation oncologist at Mount Sinai Medical Center and a Professor and Chairman of the Department of Radiation Oncology at the Mount Sinai Icahn School of Medicine. He specializes in treating patients with malignant pleural mesothelioma, lung cancer, and other thoracic malignancies. His work in introducing new technology into radiation therapy treatment for these diseases has been integral to outcomes for patients diagnosed with these challenging diseases.[1]
Dr. Rosenzweig has worked on implementing and evaluating novel techniques such as intensity-modulated radiation therapy, stereotactic body radiotherapy, deep inspiration breath hold, gated radiation therapy, and the incorporation of PET scans into the planning process for individualized patient treatment protocols.
Education and Career
Dr. Rosenzweig attended medical school at the Yale University School of Medicine and completed an internship in Internal Medicine at Beth Israel Deaconess Medical Center. He then completed a residency in Radiation Oncology at the Joint Center for Radiation Therapy at Harvard Medical School.
Before assuming his role at Mount Sinai, Dr. Rosenzweig spent 13 years at Memorial Sloan-Kettering Cancer Center. He has authored numerous textbook chapters, presented his research at numerous national and international scientific meetings, and published over 70 articles in scientific journals on his work, including:[1]
- Radiation Therapy for Malignant Pleural Mesothelioma. Thorac Surg Clin. 2020 Nov;30(4):473-480. doi: 10.1016/j.thorsurg.2020.08.006. Epub 2020 Sep 12. PMID: 33012434.
- Current readings: improvements in intensity-modulated radiation therapy for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2013 Autumn;25(3):245-50. doi: 10.1053/j.semtcvs.2013.10.004. Epub 2013 Oct 18. PMID: 24331147.
- Malignant pleural mesothelioma: adjuvant therapy with radiation therapy. Ann Transl Med. 2017 Jun;5(11):242. doi: 10.21037/atm.2017.06.25. PMID: 28706910; PMCID: PMC5497112.
Research
Dr. Rosenzweig was the principal investigator of a dose escalation study that established the maximum tolerated dose of radiation therapy that can be safely delivered.
Professional Memberships
Dr. Rosenzweig has served on many committees, including the Radiation Therapy Oncology Group (RTOG) Lung Committee, the RTOG Data Monitoring Committee, and the National Cancer Institute Clinical Trials Evaluation Panel. He has served as a Consultant to the International Atomic Energy Association. He is also a member of the Definitive and Adjuvant Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Guideline Panel of the American Society for Radiation Oncology.[1]
